Oscar L. Morey-Vargas, MD; Victor M. Montori, MD, MSc
Morey-Vargas OL, Montori VM. In at-risk patients with type 2 diabetes, saxagliptin and placebo did not differ for CV events. Ann Intern Med. ;160:JC9. doi: 10.7326/0003-4819-160-2-201401210-02009
Download citation file:
Published: Ann Intern Med. 2014;160(2):JC9.
Cardiology, Coronary Risk Factors, Diabetes, Endocrine and Metabolism.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use